The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma.
David Ilson
Research Funding - Bayer; Bristol-Myers Squibb; Roche/Genentech; Sanofi
Karyn A. Goodman
No relevant relationships to disclose
Yelena Yuriy Janjigian
No relevant relationships to disclose
Manish A. Shah
No relevant relationships to disclose
David Paul Kelsen
No relevant relationships to disclose
Nabil P. Rizk
No relevant relationships to disclose
Valerie W. Rusch
No relevant relationships to disclose
Abraham Jing-Ching Wu
No relevant relationships to disclose
Jenny Campbell
No relevant relationships to disclose
Marinela Capanu
No relevant relationships to disclose
Manjit S. Bains
No relevant relationships to disclose